HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Apr
30
VOLUNTARY ANNOUNCEMENT - PIVOTAL PHASE II/III CLINICAL STUDY OF KN026 MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AT INTERIM ANALYSIS
Apr
28
NOTICE OF ANNUAL GENERAL MEETING
Apr
25
VOLUNTARY ANNOUNCEMENT - SYH2068 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL
Apr
23
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2025
Apr
22
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Apr
22
VOLUNTARY ANNOUNCEMENT - JMT203 (ANTI-GFRAL MONOCLONAL ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr
15
VOLUNTARY ANNOUNCEMENT - OSELTAMIVIR PHOSPHATE FOR SUSPENSION OBTAINS DRUG REGISTRATION APPROVAL
Apr
14
VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr
11
VOLUNTARY ANNOUNCEMENT - SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Apr
08
VOLUNTARY ANNOUNCEMENT - JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
28
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
28
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024
Mar
21
VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
20
FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2024
Mar
18
DATE OF BOARD MEETING
Mar
18
VOLUNTARY ANNOUNCEMENT - JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Mar
13
VOLUNTARY ANNOUNCEMENT - SYH2051 (SELECTIVE ATM INHIBITOR) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
05
VOLUNTARY ANNOUNCEMENT - JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Feb
28
VOLUNTARY ANNOUNCEMENT - SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Feb
25
PROFIT WARNING
Feb
19
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYS6005 WITH RADIANCE BIOPHARMA
Feb
10
VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR ENYITAN (OMALIZUMAB FOR INJECTION) OBTAINS MARKETING APPROVAL
Feb
10
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Feb
07
VOLUNTARY ANNOUNCEMENT - SYS6017 (HERPES ZOSTER mRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL
Feb
06
CHANGE OF SHARE REGISTRAR
Jan
20
VOLUNTARY ANNOUNCEMENT - REGORAFENIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Jan
17
INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2024
Jan
16
VOLUNTARY ANNOUNCEMENT - SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jan
13
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN TABLETS OBTAINS MARKETING APPROVAL GRANTED BY NMPA
Jan
10
VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL
Jan
07
VOLUNTARY ANNOUNCEMENT - SYS6045 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL
Jan
07
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Jan
02
VOLUNTARY ANNOUNCEMENT - SYS6010 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2025 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer